ADCs: the next generation of targeted therapies
Drug Discovery World
SEPTEMBER 25, 2024
Figure 1: Major deals involving ADCs- 2024 Figure 2: Examples of FDA-approved ADCs – 2024 These include Johnson & Johnson’s $2 billion purchase of ADC specialist Ambrx in January, Genmab’s $1.8 And, last but not least, therapy with ADCs offers physicians the decisive advantage that it can be administered on site at the hospital.
Let's personalize your content